Sandoz Group AG

Discover how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its biosimilar manufacturing power and positions the company to tap a $300 bn market.

Explore how Sandoz Group AG’s launch of Afqlir and its sharp stock volatility reflect a high‑growth pharma strategy, yet raise caution for investors.

Sandoz Group AG has announced a potential acquisition of Just-Evotec Biologics, a biologics development and manufacturing facility in France, in a deal valued at approximately $300 million.